Mannitol 2.5% / Carob bean gum 0.2% oral solution
Requires a prescription from a doctor or prescriber
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 15 · 1981–2026
Showing the 50 most relevant studies, sorted by most relevant.
Anna Evelin Juhász, Tímea Klaudia Kara, Éva Csajbókné Csobod, et al.
Nutrients, 2026
Background: Guar (Cyamopsis tetragonoloba), locust bean (Ceratonia siliqua), fenugreek (Trigonella foenum-graecum), and tara (Caesalpinia spinosa) are plant-derived materials that contain galactomannans as their major polysaccharide component. Galactomannans are soluble, highly viscous, and fermentable dietary fibers widely used in the food, pharmaceutical, and cosmetic industries because of their favorable technological properties. Methods: We performed our systematic search on 16 April 2026, in MEDLINE (via PubMed), Scopus, and the Cochrane Central Register of Controlled Trials (CENTRAL), without language restrictions. Eligible randomized controlled trials compared the effects of guar gum, locust bean gum, and fenugreek on glycemic parameters, lipid profile, and body weight-related outcomes in healthy adults or patients with metabolic disorders. Results: A total of 50 randomized controlled trials were included in the analysis. Of these, 27 investigated guar gum, 20 fenugreek (12 seed powder, 7 seed extract, 1 leaf extract), two mixed galactomannan preparations, and one locust bean gum intervention. Considerable heterogeneity was observed across studies regarding participant characteristics, intervention doses, and treatment duration. Nevertheless, fenugreek-derived preparations consistently improved glycemic outcomes. In contrast, guar gum demonstrated more consistent effects on lipid parameters. Effects on body weight and body mass index were less consistent across studies. Conclusions: Our findings suggest that the metabolic effects of galactomannans are source-dependent, with fenugreek-based interventions appearing to have greater potential for improving glycemic outcomes, while guar gum may be more effective in improving lipid parameters. Since these fibers can be easily consumed in the form of dietary supplements, it is worth considering their regular, daily intake. The protocol was prospectively registered in the PROSPERO database (CRD420261368159).
Abstract licence: CC BY 4.0
S. Barak, Deepak Mudgil
International journal of biological macromolecules, 2014
Andreas Loullis, Eftychia Pinakoulaki
European Food Research and Technology, 2018
Zunaira Basharat, Muhammad Afzaal, F. Saeed, et al.
International Journal of Food Properties, 2023
R. Rodríguez-Solana, A. Romano, J. Moreno-Rojas
Processes, 2021
Amiri MS, Mohammadzadeh V, Yazdi MET, et al.
2021
- Drug Carriers
- Nanomedicine
- Plant Mucilage
Gums are carbohydrate biomolecules that have the potential to bind water and form gels. Gums are regularly linked with proteins and minerals in their construction. Gums have several forms, such as mucilage gums, seed gums, exudate gums, etc. Plant gums are one of the most important gums because of their bioavailability. Plant-derived gums have been used by humans since ancient times for numerous applications. The main features that make them appropriate for use in different applications are high stabilization, viscosity, adhesive property, emulsification action, and surface-active activity. In many pharmaceutical formulations, plant-based gums and mucilages are the key ingredients due to their bioavailability, widespread accessibility, non-toxicity, and reasonable prices. These compete with many polymeric materials for use as different pharmaceuticals in today's time and have created a significant achievement from being an excipient to innovative drug carriers. In particular, scientists and pharmacy industries around the world have been drawn to uncover the secret potential of plant-based gums and mucilages through a deeper understanding of their physicochemical characteristics and the development of safety profile information. This innovative unique class of drug products, useful in advanced drug delivery applications, gene therapy, and biosynthesis, has been developed by modification of plant-based gums and mucilages. In this review, both fundamental and novel medicinal aspects of plant-based gums and mucilages, along with their capacity for pharmacology and nanomedicine, were demonstrated.
Abstract licence: CC BY
J. L. DOUBLIER, B. LAUNAY
Journal of Texture Studies, 1981
Yingjie Chen, Junyan Guo, A. Alamri, et al.
Carbohydrate polymers, 2024
Baojie Zhu, M. Z. Zayed, Hua-xu Zhu, et al.
Chinese Medicine, 2019
Salah Laaraj, S. Salmaoui, M. Addi, et al.
Journal of Food Quality, 2023
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.